Breaking News

The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.

CEO Patrick Soon-Shiong said that GPS Cancer test revenues rose threefold year over year during Q4, and 606 GPS tests were ordered, up from 325 a year ago.

The company posted Q4 revenues of $6.6 million, down from $6.7 million in Q4 2016 and shy of the consensus Wall Street estimate of $6.7 million.

A new study has uncovered about 100,000 unique extrachromosomal circular DNAs in samples from 16 men.

The researchers used DNA methylation profiles to define 82 central nervous system tumor classes, some of which differed from WHO tumor classes.

The companies will join their respective technologies into a precision oncology testing and analysis offering.

The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.

The companies are accelerating the pace of an existing collaboration with the goal of detecting SMA "2+0" carrier status.

The companies also agreed to establish a working group to explore the development of standard formulas and definitions for the validation of genomic profiling assays.

In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.

The researchers said their study uncovered an unmet need that could be addressed by changing how genetic counseling is included in clinical practice.

The suit alleged that Precipio failed to meet the obligations of a securities agreement signed by Transgenomic, which it acquired last year.

New ancient DNA studies have revealed female-biased migrations into Bavaria during the Middle Ages and more ancient Neolithic farmer expansions into Iberia.

The collaborative study includes testing urine samples from patients who have an increased risk for complicated urinary tract infections.

The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.

The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.

The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.

The firm said the increase in overall revenues was due largely to a 4 percent increase in clinical labs revenues, while product revenues inched up 1 percent year over year.

Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.

The researchers uncovered more than 20 new stroke-associated genetic loci, some of which are the targets of antithrombotic drugs.

Researchers saw clinically actionable heart disease mutations in fewer than 5 percent of sudden infant death syndrome cases interrogated by molecular autopsy.

The companies are aiming to codevelop, comarket, and improve the integration of the Evosep One LC system with Bruker's timsTOF Pro mass spec.

Last week, GenomeWeb's readers were most interested in Danaher's acquisition of genomics consumables firm Integrated DNA Technologies.

The researchers conducted a genome-wide association study and other analyses using about 47,000 research participants from 23andMe.

Researchers used a capture Hi-C strategy to identify candidate target genes and pathways at dozens of loci previously linked to breast cancer susceptibility.


Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.